Community-acquired pneumonia
Second line
Second-line for community-acquired pneumonia in patients with β-lactam allergy or at risk of resistant pneumococcus. /ATS 2019 and SEPAR 2024 set high-dose or amoxicillin + macrolide as first-line outpatient CAP. Moxifloxacin (400 mg once daily for 5 days) is used in allergy or first-line intolerance, or with risk of resistant Streptococcus pneumoniae.